<p>Avalon Capital Management 在最近向 SEC 提交的文件中表示，该公司在第二季度增持了 Danaher Co.（NYSE:DHR - 免费报告）的持股，增幅达 250.5%。该基金在本季度购入额外的 2,718 股后，持有这家企业的 3,803 股股票。Avalon Capital Management 在最近一次向 SEC 提交的文件中，持有的 Danaher 股票价值为$950,000。</p>
<ul>
<li>Danaher 股票会在 2024 年创下新高吗？</li>
</ul>
<p>其他许多大型投资者最近也调整了他们对该企业的持股。Leonard Rickey Investment Advisors P.L.L.C.在第二季度购入了 Danaher 股票的新头寸，价值约$204,000。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 在第二季度增持了 Danaher 的持股，增幅为 6.5%。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 现在拥有 6,750 股这家企业的股票，价值$1,686,000，上季度购入额外的 412 股。Arcus Capital Partners LLC 在第二季度增持了 Danaher 的持股，增幅为 12.0%。Arcus Capital Partners LLC 现在拥有 3,135 股这家企业的股票，价值$783,000，上季度购入额外的 335 股。&amp;PARTNERS 在第二季度购入了 Danaher 的新股份，价值约$1,257,000。最后，Geneos Wealth Management Inc.在第二季度增持了 Danaher 的持股，增幅为 3.9%。Geneos Wealth Management Inc.现在拥有 14,826 股这家企业的股票，价值$3,704,000，上季度购入额外的 554 股。目前，该股有 79.05% 的股份由机构投资者持有。</p>
<h2>Danaher 股价上涨 0.6%</h2>
<p>DHR 周五上涨$1.65，报价$269.48。公司交易了 1,367,720 股股票，相比其平均交易量 2,820,898 股有所减少。该股的 50 天移动平均价格为$258.42，200 天移动平均价格为$254.18。Danaher Co.的 52 周最低价为$182.09，最高价为$281.70。该公司的市值为$1996 亿美元，市盈率为 45.39，PEG 比率为 4.62，贝塔系数为 0.83。该公司的资产负债比为 0.33，流动比率为 1.43，速动比率为 1.04。</p>
<ul>
<li>三大蓝筹股 - 现在最值得购买的蓝筹股</li>
</ul>
<p>Danaher（NYSE:DHR - 获取免费报告）最近公布了截至 7 月 23 日星期二的季度收益数据。该企业报告本季度每股收益为$1.72，超过了分析师预期的$1.57，超出$0.15。Danaher 的净利润率为 16.94%，净资产收益率为 11.06%。该季度，该公司的营收为 57.4 亿美元，超过了 55.9 亿美元的共识预期。与去年同期相比，该公司的营收同比下降了 2.9%。卖方分析师平均预计，Danaher Co.本财年的每股收益将达到 7.59 美元。</p>
<h2>分析师设定新的价格目标</h2>
<p>DHR 已成为多家研究分析师报告的热门话题。Stifel Nicolaus 将 Danaher 的目标股价从 235.00 美元上调至 250.00 美元，并在 7 月 24 日星期三的研究报告中给予该公司 “持有” 评级。StockNews.com 在 6 月 25 日星期二的报告中，将 Danaher 的股票评级从 “买入” 调降至 “持有”。加拿大皇家银行在 7 月 24 日星期三的报告中，将 Danaher 的目标股价从 297.00 美元上调至 300.00 美元，并给予该股 “表现优异” 评级。巴克莱将 Danaher 的目标股价从 270.00 美元上调至 285.00 美元，并给予该股 “等权重” 评级。最后，Robert W. Baird 将 Danaher 的目标股价从 271.00 美元上调至 278.00 美元，并给予该股 “表现优异” 评级。六位分析师对该股的评级为持有，十二位对该公司的股票发出买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “中等买入”，共识价格目标为 276.88 美元。</p>
<ul>
<li>医疗股票 - 最值得购买的医疗科技股票</li>
</ul>
<p><strong>获取我们关于 Danaher 的最新报告</strong></p>
<h2>内部人士押注</h2>
<p>在其他 Danaher 的消息中，首席财务官 Matthew Mcgrew 于 8 月 1 日星期四出售了 16,172 股公司股票。这些股票的平均价格为 279.84 美元，总价值为 4,525,572.48 美元。在完成交易后，首席财务官现在直接持有公司股票 29,407 股，价值 8,229,254.88 美元。该交易已在与证券交易委员会的法律文件中披露，可以通过此超链接访问。另外，高级副总裁 Brian W. Ellis 于 7 月 25 日星期四以 275.16 美元的平均价格出售了公司的 9,600 股股票。此次交易总价值为 2,641,536.00 美元。交易完成后，这位高级副总裁现在直接持有公司股票 20,230 股，价值 5,566,486.80 美元。关于此次交易的披露可以在此处找到。内部人士在过去 90 天内出售了价值 10,786,944 美元的 38,707 股公司股票。公司内部人士持有公司股份的比例为 11.10%。</p>
<h2>Danaher 公司简介（免费报告）</h2>
<p>丹纳赫公司在全球设计、制造和销售专业、医疗、工业和商业产品和服务。生物技术部门提供生物工艺技术、耗材和服务，推动、加速和整合治疗药物的开发和生产；细胞系和细胞培养培养基开发服务；用于制造的细胞培养基、工艺液体和缓冲液、色谱树脂、过滤技术、无菌灌装；一次性硬件和耗材以及服务，如全套生产套件的设计和安装；实验室过滤、分离和纯化；实验室规模的蛋白纯化和分析工具；试剂、膜和服务；以及医疗保健过滤解决方案。</p>
<h2>参考资料</h2>
<ul>
<li>五只我们比丹纳赫更喜欢的股票</li>
<li>关于标记计算器</li>
<li>Lumen：上个月表现优异，但仍有警示信号</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>百度强劲季度证明迈克尔·伯里的明智选择</li>
<li>经纪排名在股票选择中的重要性</li>
<li>Intuit 击败第四季度盈利：人工智能、股息和增长策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg"/></p>
<p><em>这则即时新闻警报是由市场数据和 narrative science 技术生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 44 年华尔街老兵：&#34;不可逆转的破坏即将降临美国&#34; (来自 InvestorPlace)(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTgx"/></p>
<h2>现在是否值得投资$1,000 美元购买丹纳赫？</h2>
<p>在考虑投资丹纳赫之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买，而丹纳赫不在名单上。</p>
<p>尽管目前分析师对丹纳赫的评级为&#34;中等买入&#34;，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

丹纳赫

<p>Avalon Capital Management 在第二季度增持了丹纳赫公司（NYSE：DHR）的持股，增加了 250.5%，购入了 2,718 股，总持股量达到 3,803 股。该股上涨了 0.6%，报价为$[current price]。其他投资包括 Leonard Rickey 投资顾问和 Bay Colony 咨询集团。分析师设定了$[target price] 的共识目标价，平均评级为 “中等买入”。丹纳赫的第二季度收益超过了预期，报告的每股收益为$0.72。首席财务官 Matthew Mcgrew 最近出售了 16,172 股股票，价值约$[sale price]</p>

<p>Avalon Capital Management lifted its holdings in Danaher Co. (NYSE:DHR - Free Report) by 250.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,803 shares of the conglomerate's stock after buying an additional 2,718 shares during the quarter. Avalon Capital Management's holdings in Danaher were worth $950,000 as of its most recent filing with the SEC.</p>
<ul>
<li>Will Danaher stock hit new highs in 2024?</li>
</ul>
<div class="lb-trans"><p>Avalon Capital Management 在最近向 SEC 提交的文件中表示，该公司在第二季度增持了 Danaher Co.（NYSE:DHR - 免费报告）的持股，增幅达 250.5%。该基金在本季度购入额外的 2,718 股后，持有这家企业的 3,803 股股票。Avalon Capital Management 在最近一次向 SEC 提交的文件中，持有的 Danaher 股票价值为$950,000。</p>
<ul>
<li>Danaher 股票会在 2024 年创下新高吗？</li>
</ul>
</div><p>A number of other large investors also recently modified their holdings of the business. Leonard Rickey Investment Advisors P.L.L.C. bought a new position in shares of Danaher in the 2nd quarter worth about $204,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its position in Danaher by 6.5% in the 2nd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 6,750 shares of the conglomerate's stock valued at $1,686,000 after purchasing an additional 412 shares during the last quarter. Arcus Capital Partners LLC lifted its position in Danaher by 12.0% in the 2nd quarter. Arcus Capital Partners LLC now owns 3,135 shares of the conglomerate's stock valued at $783,000 after purchasing an additional 335 shares during the last quarter. &amp;PARTNERS bought a new stake in Danaher in the 2nd quarter valued at about $1,257,000. Finally, Geneos Wealth Management Inc. lifted its position in Danaher by 3.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 14,826 shares of the conglomerate's stock valued at $3,704,000 after purchasing an additional 554 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他许多大型投资者最近也调整了他们对该企业的持股。Leonard Rickey Investment Advisors P.L.L.C.在第二季度购入了 Danaher 股票的新头寸，价值约$204,000。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 在第二季度增持了 Danaher 的持股，增幅为 6.5%。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 现在拥有 6,750 股这家企业的股票，价值$1,686,000，上季度购入额外的 412 股。Arcus Capital Partners LLC 在第二季度增持了 Danaher 的持股，增幅为 12.0%。Arcus Capital Partners LLC 现在拥有 3,135 股这家企业的股票，价值$783,000，上季度购入额外的 335 股。&amp;PARTNERS 在第二季度购入了 Danaher 的新股份，价值约$1,257,000。最后，Geneos Wealth Management Inc.在第二季度增持了 Danaher 的持股，增幅为 3.9%。Geneos Wealth Management Inc.现在拥有 14,826 股这家企业的股票，价值$3,704,000，上季度购入额外的 554 股。目前，该股有 79.05% 的股份由机构投资者持有。</p>
</div><h2>Danaher Stock Up 0.6 %</h2>
<div class="lb-trans"><h2>Danaher 股价上涨 0.6%</h2>
</div><p>DHR traded up $1.65 on Friday, reaching $269.48. 1,367,720 shares of the company traded hands, compared to its average volume of 2,820,898. The stock's 50 day moving average price is $258.42 and its 200-day moving average price is $254.18. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a market cap of $199.60 billion, a price-to-earnings ratio of 45.39, a PEG ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.</p>
<ul>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
</ul>
<div class="lb-trans"><p>DHR 周五上涨$1.65，报价$269.48。公司交易了 1,367,720 股股票，相比其平均交易量 2,820,898 股有所减少。该股的 50 天移动平均价格为$258.42，200 天移动平均价格为$254.18。Danaher Co.的 52 周最低价为$182.09，最高价为$281.70。该公司的市值为$1996 亿美元，市盈率为 45.39，PEG 比率为 4.62，贝塔系数为 0.83。该公司的资产负债比为 0.33，流动比率为 1.43，速动比率为 1.04。</p>
<ul>
<li>三大蓝筹股 - 现在最值得购买的蓝筹股</li>
</ul>
</div><p>Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts' consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.05 earnings per share. The firm's revenue was down 2.9% on a year-over-year basis. On average, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Danaher（NYSE:DHR - 获取免费报告）最近公布了截至 7 月 23 日星期二的季度收益数据。该企业报告本季度每股收益为$1.72，超过了分析师预期的$1.57，超出$0.15。Danaher 的净利润率为 16.94%，净资产收益率为 11.06%。该季度，该公司的营收为 57.4 亿美元，超过了 55.9 亿美元的共识预期。与去年同期相比，该公司的营收同比下降了 2.9%。卖方分析师平均预计，Danaher Co.本财年的每股收益将达到 7.59 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>DHR has been the topic of several research analyst reports. Stifel Nicolaus raised their target price on shares of Danaher from $235.00 to $250.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, June 25th. Royal Bank of Canada boosted their target price on shares of Danaher from $297.00 to $300.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 24th. Barclays boosted their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, July 24th. Finally, Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $276.88.</p>
<ul>
<li>Medical Stocks - Best Medical Technology Stocks to Buy</li>
</ul>
<div class="lb-trans"><p>DHR 已成为多家研究分析师报告的热门话题。Stifel Nicolaus 将 Danaher 的目标股价从 235.00 美元上调至 250.00 美元，并在 7 月 24 日星期三的研究报告中给予该公司 “持有” 评级。StockNews.com 在 6 月 25 日星期二的报告中，将 Danaher 的股票评级从 “买入” 调降至 “持有”。加拿大皇家银行在 7 月 24 日星期三的报告中，将 Danaher 的目标股价从 297.00 美元上调至 300.00 美元，并给予该股 “表现优异” 评级。巴克莱将 Danaher 的目标股价从 270.00 美元上调至 285.00 美元，并给予该股 “等权重” 评级。最后，Robert W. Baird 将 Danaher 的目标股价从 271.00 美元上调至 278.00 美元，并给予该股 “表现优异” 评级。六位分析师对该股的评级为持有，十二位对该公司的股票发出买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “中等买入”，共识价格目标为 276.88 美元。</p>
<ul>
<li>医疗股票 - 最值得购买的医疗科技股票</li>
</ul>
</div><p><strong>Get Our Latest Report on Danaher</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Danaher 的最新报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士押注</h2>
</div><p>In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company's stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company's stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the company's stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 38,707 shares of company stock valued at $10,786,944 over the last ninety days. Corporate insiders own 11.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Danaher 的消息中，首席财务官 Matthew Mcgrew 于 8 月 1 日星期四出售了 16,172 股公司股票。这些股票的平均价格为 279.84 美元，总价值为 4,525,572.48 美元。在完成交易后，首席财务官现在直接持有公司股票 29,407 股，价值 8,229,254.88 美元。该交易已在与证券交易委员会的法律文件中披露，可以通过此超链接访问。另外，高级副总裁 Brian W. Ellis 于 7 月 25 日星期四以 275.16 美元的平均价格出售了公司的 9,600 股股票。此次交易总价值为 2,641,536.00 美元。交易完成后，这位高级副总裁现在直接持有公司股票 20,230 股，价值 5,566,486.80 美元。关于此次交易的披露可以在此处找到。内部人士在过去 90 天内出售了价值 10,786,944 美元的 38,707 股公司股票。公司内部人士持有公司股份的比例为 11.10%。</p>
</div><h2>Danaher Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Danaher 公司简介（免费报告）</h2>
</div><p>Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.</p>
<div class="lb-trans"><p>丹纳赫公司在全球设计、制造和销售专业、医疗、工业和商业产品和服务。生物技术部门提供生物工艺技术、耗材和服务，推动、加速和整合治疗药物的开发和生产；细胞系和细胞培养培养基开发服务；用于制造的细胞培养基、工艺液体和缓冲液、色谱树脂、过滤技术、无菌灌装；一次性硬件和耗材以及服务，如全套生产套件的设计和安装；实验室过滤、分离和纯化；实验室规模的蛋白纯化和分析工具；试剂、膜和服务；以及医疗保健过滤解决方案。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Danaher</li>
<li>About the Markup Calculator</li>
<li>Lumen: Among Top Performers Last Month, Still Has Warning Signs</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Baidu's Strong Quarter Proves a Smart Pick for Michael Burry</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy</li>
</ul>
<div class="lb-trans"><h2>参考资料</h2>
<ul>
<li>五只我们比丹纳赫更喜欢的股票</li>
<li>关于标记计算器</li>
<li>Lumen：上个月表现优异，但仍有警示信号</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>百度强劲季度证明迈克尔·伯里的明智选择</li>
<li>经纪排名在股票选择中的重要性</li>
<li>Intuit 击败第四季度盈利：人工智能、股息和增长策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DHR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由市场数据和 narrative science 技术生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ 44-year Wall Street Vet: “Irreversible destruction is coming to America” (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 44 年华尔街老兵：&#34;不可逆转的破坏即将降临美国&#34; (来自 InvestorPlace)(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTgx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9181&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Danaher right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元购买丹纳赫？</h2>
</div><p>Before you consider Danaher, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资丹纳赫之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买，而丹纳赫不在名单上。</p>
</div><p>While Danaher currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管目前分析师对丹纳赫的评级为&#34;中等买入&#34;，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Avalon 资本管理公司提升了丹纳赫公司（纽约证券交易所代码：DHR）的股票持有量